Beam Therapeutics Inc. (NASDAQ:BEAM) saw its shares rise 1.7% in premarket trading Monday after releasing updated results ...

The safety profile remained consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. The most common treatment-emergent adverse events included ...

In the analyses, 68% percent of patients received prior CHOP-based therapy, 35% had salvage chemotherapy, 20% had autologous stem cell transplant, 17% had an HDAC inhibitor, and 38% had prior exposure ...

Beam Therapeutics (BEAM) announced new safety and efficacy data from its BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel, formerly ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean Hemoglobin F (HbF) Induction of ...

Inside human cells, biology has pulled off the ultimate packing job, figuring out how to fit six feet of DNA into a nucleus ...